{"ticker": {"uuid": "34d3fbdb-ab3e-4e73-9d4a-f674238a0199", "symbol": "NUZ", "name": "Neurizon Therapeutics Limited", "exchange": "ASX", "country": "AU", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "What Does Faster Trial Enrolment Mean for Neurizon Therapeutics (ASX:NUZ)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQN1VESjRSZS1BMlJrR19vOEtaVUJNSkpYVGdEd2FxLWVLazZYV3VubmI0SnM5bFpqWlU4R3JUazFoSl9rMW93aWlMWGFvc0VBWGRsV1JSalprNExsM3NZZllNTGhmQjhKQ1lpdlJYbTRVMTkyb08za3EyczkyRlhjcmRmbmRMMkZZSWtKU3RxQ0R3RUl4OHRvT1Q0SjJiakZmTnh1S2dFRkd3RTYwS1E?oc=5", "source_name": "Kalkine", "published_at": "2026-07-17T07:56:00+00:00", "published_display": "17 Jul 2026 07:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon\u2019s ALS treatment trial results expected in late Q2 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPd0F3a3BManZEQldtZ0hQZW4tWC1kdDVoQ2tKMjM4ai1OMmEzT1ZLNzJIajNJaWd6U2FGMjByc1RZQWNCMTJ6NF9WLWFSTXh0NWpxVGI4dnlnSm1NUFVvZkszdUduLXFJVTJfZmhNR251dVk4RWE0ZWpwd1Bub1FPTWtSb05GdFNvSVE3elhHbTFFV3dnQ3FRQmhJcnF6a2Y2cllRZ0ZieHEzZHVBaTJZTmxKSFVicE45eE04?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T06:33:10+00:00", "published_display": "17 Jul 2026 06:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon accelerates trial timelines as enrolment completes", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOdXNyTUVNblFpbDFPZndkQ1hva29Kc3J1M0h3NlhBYlRvUDNVaWsyZzNROXJTczNndVZjZU5HbGlBcEhORktEYkdCQlpHWUZKWVNNZEdZZ19HdzJLRFhxYUQzTmUzdFRBb1NmVU1nUzR2VFowOUNNZk00NmE5OEd1RE1mVm9Md0JMRW9od2p1LW5feTFVdFZ3Q19lOA?oc=5", "source_name": "grafa.com", "published_at": "2026-07-17T03:00:35+00:00", "published_display": "17 Jul 2026 03:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Neurizon Therapeutics (ASX:NUZ) Leading the Next Wave of ASX Biotech Small Caps?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxON253NC1NZmJHY1dFRGhNdmJVamVEcmJwaGpuT0pnbTI2TWdBVm5NQUJKX1JzQ3Rja2xPZFhKcjNiQnVoOUFBVTBDLUtWdVA3ODBZN1FUVURsbk4tenhHZHQzdzViUGEwX2N1QmVIcnVVZ0h4Q0lra05xQXBnaDh0d3cxcFVnUVNCcVFVdmRHczZPdDh6QVJFZnloazB3X3dEaTVHWGxaZ1NaZnBPaEVpVDFxaHlZQ0NNYjJ0Y2FpamlKQnBUTUE?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-15T04:30:00+00:00", "published_display": "15 Jul 2026 04:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon Therapeutics (ASX:NUZ) Reaches Key ALS Trial Milestone", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTUh5S2RGZjFFbkVRanljY2poYnVSVjRDOS1NbHFMWjg3Z3dQcm1DQm41eDMtbEFxMzY5OWl2UTNBZkVieTJOV3ZrZGIyZ3psbkR3MjFUbk1qMVhfWV81LUNUalNQcEtBX1BISU9pWFVtb08zVE5kLWFyOVNCcWRfTVUxRXMwUGxTQVA1YkxUb20yU3dTaEhTQlppaVFOQ3NNcUNKeDVpMA?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon director Marcus Hughes lifts stake with June share purchases", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQTTY0SmNDeTZEUmhhMkVhdGJQa3JQNnVXNUZDa3E5ZWVhaWhrMkhaM1dwcWN4RnNydGxaYmZYdXBkOFNvTnJ1SkdONmpFbWNBS2dUWDVfUmFLUDk5M25YTUF2X1BrWVZ1NDQ1dC1QOXdBMUcxWllwUFR2RVpvTzh4eEhPUlpjSVN4WFNQNFdjd3cyRUFPSHEyQlYzRjBNQXNGczkxMTd2Vk5nOTlWX1BXMEVMZTZ4bmU3ZDNYOGF2WW9LTmEzWTEzUEVpUUhNd1A2SFNWNTkxdU9wWEd2N09vN080NG8?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon (ASX: NUZ) Unveils New NUZ-001 ALS Mechanism Data at BIO International Convention 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPOHR3VXAyMG54anhDWXBBVEVlRC1vZWl0bkhOMEJ2bVpEUFhYQVhqWEhqcjB2cURpc1VuaW1BSlRtR09BRWdIZ2c2ck1ScDBxZTBzV2lWOXpmclVmYVZLNDU3a2lyRFBka1RGMHlNLU9hNlM5UUp6UHZ2TzR1ZndhRHlPSkxiWUZzVVVtYmNBZVJDZGdvRk10bXVNamx5U2NOQmhUa2ZPZG1lSzVXLWxLRDhZbVlGRmdaWG5aQVhJc1V2cVVael8yYWJpdw?oc=5", "source_name": "Kalkine", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX: NUZ \u2014 Neurizon Therapeutics Locks In Drug Supply as MND Program Momentum Builds", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQX2hQZHVOVExDNnlHNnYxS3c5SDNIVGZoZnFmNE51WnROTUlBSEJrUkNnMnJQU0VOdHlybzlBY1hrWU1FckFHVFRLOFlkbFU5VkpBOTVKX25wbGNKUU1mYmNhdDJuMFA1S2Z2Vl8yN3BNQmVQZ1BTSEk3VG0yRXczSnY3ZnVQT1VXenJtZ255U2Z5X1pGVUZFSzc5OWJKRzlOMTZLUnZONEU2cGt3NDNFekd2ZWhnRGxGNmdYSw?oc=5", "source_name": "Kalkine", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon Therapeutics (ASX NUZ) Shares Jump After Elanco Supply Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQMU12UlRtanA2TGNjcF91MkMzWmprOGlYbGJsal9IMGhvWUlNVWlsVWVDRHhuVzJqNXltcUthS3NBVjdIU1gzaVRseW1RLVN3MVdVYjZTVEVuLXo5SE14XzZ5ZlZ1RThyVEhiN0s3V0J2bVZSNkgxTXEyc19ZT0tCczk5eThJWXN0T3h6R1NYRnFZbVJLWTVycjdtTk1TRTcxWFo1Z3hGTUk?oc=5", "source_name": "Kalkine", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon Therapeutics (ASX:NUZ) Is in Focus Following HEALEY ALS Trial Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPTTEzOWZIVWVFMkptRnNxZ1FnREl5TkREaUwtNGNPaTdTUU9iWVFmZFBDUVotdGNReFFzRkFwQWhkT0pGSWpIOXR6c0JETUxBRmxZZXZXT2JrbWtDd3hJNXRTRERDTWI3Z3JTLVY1UTh6dFMtNU84VFFCZV9XTXMzNGhLT0xuVnE1eUdtRGRjQngzaHJldFVHa3N5OWNLcWtxSDFad0ZlN1ByUS1rTDg2Uk5Vbw?oc=5", "source_name": "Kalkine", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Neurizon launches $11.3m shortfall auction after rights issue", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQNGJoRTRHOTJoRzBMTjZEUEVxOUVzei1HLUdNWEdmYlNVLWRLVFRYUXRCRG1nMzRZV3VLX2RoMm9iYy14SFFlYm5fNV9jZVFTVHJhcG03SHFYb0RMTWdIWUpYeHJEOGhsWERuWWp1SThBTEtkLTBIdk9TdnVZTmxLNnNLRHRHcFZjckZiazZ6clFIc0VORGdjZDlITmgxRUQyY0QtZlIyTTJ5bkZSRzUxX2JwajNEME0?oc=5", "source_name": "AFR", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon Therapeutics (ASX:NUZ) Rises as New Data Strengthens Case for ALS Drug Candidate", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNb0V0VTlscy10ZDZmX1g0eXRFclFzM0U5MUVKa1VGVU5KaGVrMENkaERSR2NGb3Badk9Xa3M0Q3dnQThYUGduVDR1cWtERGc1WVFiaDV0R0N3aEJTaXZIbVN4QlN3dVg0aFFrZmNBS3RWR2lYNDdtaTBPNlJNUmFtSWplcTVXLV91THAzSTUzeUlEdFFzOVliTERiTERESGFYSEtWU091RkY1NUNtUm9za3dkcm53LXYxdjNLaDBQaER4aVk?oc=5", "source_name": "Kalkine", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon Therapeutics Chief Executive Officer Resigns, Shares Down 13%", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOcWpndllPSTV4WTFuYzVMN1ltcWQxSWNWYVNma2xTd284VW9zY0xyR3RpWkhNTXJaaEFzd1llbFdHbmNfS21lNVYxMGFodFBRV1VQOHlnRGtubE4yS3NQM29vLW1mRVBBVWJiOUhGckJHTXIzY3BZZThKQUZIOGtnTUEwNk1iRF9IRG5LRGhxbG41NjJ4cEc0bUxqd3U3S0VtZkViMHJEdGxHazRVTHNZ?oc=5", "source_name": "Moomoo", "published_at": "2026-03-15T07:00:00+00:00", "published_display": "15 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNYmt3SXFUcVdrVFR5elV5NVFMTUg1OUstdDZvWHhrbEtXaXpZVVRtQ0k3YWVTbVZzYTNuUF9qb2hfc1NNNFFkVF9tanBfSDZmRWtnV2tEWEpJT2xyN1VLaDRUX2pwTnBqVVlrdmNVUTdaZm1XSTM0d2Z5WlM2UjB6YklyTlRTZ0M5VGlid1d4b3NsUVJDN1hfR3dlMlItam03V2s5M09aaTFZaFdtWGR5a3p0RERyaGFfbzFBc2V3?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon locks in global trademark protection", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Australian", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon Therapeutics Secures Over $44M in Funding to Advance HEALEY ALS Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQSWtOcWUtMXlWOEtRQnoxUmpYSjhlWVc1UTZiclZ6WVZ5LU5mUm15UUtYTnlrc3NUbWlzVGdrUnN3WDVpR2JpTzRjY2JoNnJMc1BSUjMweE1NTmhJVWFxRHdKclNvakgzQVZkYlZEUTZsbUM1WTZ6TmNjRkF2ejRXSExkd2UteEc3bjlJMDRxbC1FTURHMTFIM2o3TW44Z0ljSDdwZFZMUUVacDZDMEtF?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-12-22T08:00:00+00:00", "published_display": "22 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insights: Neurizon Therapeutics Ltd (ASX:NUZ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFB6TkZXNVo4c09WSXdwYnJtTjNOVW5SOHRsOXhzUXlOTzNDUWstVU5MT3prNjlJRGZBV25xSzBWLWEzVGUzeDQ4ajNBem1lQ3pS?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-10-30T16:22:03+00:00", "published_display": "30 Oct 2025 16:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Break it Down: Neurizon secures Australian patent for its lead ALS drug candidate", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOT2lKal9McEhWeHJiT3c0WHRvT1k0Qk9KblZabmhiVV84ZlZHMkd0UXRWYjdJeVYwRmdNcm5GSmZNRGtCbGlFS211Z3pMVHZUaDNIZUZaSDZXRTdMWkJiNUtCbTljYWF2ZEdRc3d4dFM0TVZzYThncUlnMlViNGRfMDViaWpsQ29CUDRsOWYxUFljZ3VkVVFlRFlQeE5ncUhFUE5DeC1QeGlVaDk1bDZsY2lCOHdHU1BfWlVTLUVDMFk5em00c0RTMEZDZ0NKUQ?oc=5", "source_name": "Stockhead", "published_at": "2025-10-21T07:00:00+00:00", "published_display": "21 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "On track: Analysts hail FDA lift as turning point for Neurizon\u2019s ALS therapy ambitions", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOcjYyUEZBM3V0dEtXR1AxbHVVY1puVmhBaS1tSUNhVVpzMWdfNkRpSXJLTVhXNGxiOTlzU09aaF9DaUtxZ1JDTXo3Tjh4Yk1UVEpIZ25vY0ZiYzBIbTVMNUVhOUlxWVF2WjBROFhTUG5RZ0lEeFYxc0dQTXRwTFB6SWdxQU92dGdLb0hwNGRGTXNwNFR6RG45S3lvdzY1NjJvRzl3?oc=5", "source_name": "Stockhead", "published_at": "2025-10-09T07:00:00+00:00", "published_display": "09 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Lifts Clinical Hold on Neurizon Therapeutics Lead Investigational Drug NUZ-001", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQaDBOSFlpOG02M192TDQ4cVRWbG9SRVVGLVJZejRyYTVMMzc0cVFDUmhWcUNaNVRvXzRmcmJNalRGMzBZLUZwNlZGZXVnZ2ZtNVdlWF9ZeUJQTHBXV2pnczRpOEVnbnF6R1VDc0tnSko5cVlGaVl0VGZHZ3JEU3VGNmJYLXp4V3doWVlpckhLWE41a1k4cWhDa0xsMkhZeGY0NmJYQ1lESTc?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2025-10-06T07:00:00+00:00", "published_display": "06 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon Therapeutics Limited (ASX: NUZ) - Announcements", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNTHNOLU1nQmdFei1NUC1EVHdmLVZnckYyR19QZjU5N0xlTVpHQ3poQ3BzQnRPZVVKbldBOEptaXpCbjFNRjAzN2N4S2RTaF92aU9hNWg2S2tIZU0tWm5JVjZfTUJiRV9JdVRmM215bXBydTdkMHNoa3VrVGhUdzFPeTBkN0VyR1J6LWNtZHNiQ1FFeW5FTGxVX04yOHFydw?oc=5", "source_name": "intelligentinvestor.com.au", "published_at": "2024-10-15T07:18:47+00:00", "published_display": "15 Oct 2024 07:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmAust affirms corporate strategy with name change to Neurizon Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNZkFfRzJNRjRfbmotaXF2dFhrQkFmNWpYWlJTbDJOcFR1Nk90Z0R3OXUzQWVTa00zZzlZa01DcXplUUxqN3RqNWwyWE1KaDNxTmFQVXpuNnhzZDd2YkZOMTIteURPWFYtMGE0aWRkWHNCTXZ6bUc2X1NBcDEzeEVzaTM1RHlEWmU1QW1qS1I4cEw0Q05SUkhjYUl0X0lnSzl6alFES3hBVHVUaHgyeG1yQUFuTmx0eWtWQ2E3WHVqbWRyLXpndmRyRlVGcFJwZEk?oc=5", "source_name": "PR Newswire", "published_at": "2024-10-15T07:00:00+00:00", "published_display": "15 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmAust rebrands as Neurizon Therapeutics", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Australian", "published_at": "2024-10-15T07:00:00+00:00", "published_display": "15 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NUZ Stock Price and Chart \u2014 ASX:NUZ", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE9NdmdHSEFWWjQ0bDVxRC1mbjl6SkdEbUU5UzhabE5ESVc2U0JqQWpia0VnU2YzNDUydjU2Y2ROMThsQ0lSZHhXMS1tTUswUWVpTUZfLWJDUQ?oc=5", "source_name": "TradingView", "published_at": "2024-10-15T01:37:38+00:00", "published_display": "15 Oct 2024 01:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "What Does Faster Trial Enrolment Mean for Neurizon Therapeutics (ASX:NUZ)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQN1VESjRSZS1BMlJrR19vOEtaVUJNSkpYVGdEd2FxLWVLazZYV3VubmI0SnM5bFpqWlU4R3JUazFoSl9rMW93aWlMWGFvc0VBWGRsV1JSalprNExsM3NZZllNTGhmQjhKQ1lpdlJYbTRVMTkyb08za3EyczkyRlhjcmRmbmRMMkZZSWtKU3RxQ0R3RUl4OHRvT1Q0SjJiakZmTnh1S2dFRkd3RTYwS1E?oc=5", "source_name": "Kalkine", "published_at": "2026-07-17T07:56:00+00:00", "published_display": "17 Jul 2026 07:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon\u2019s ALS treatment trial results expected in late Q2 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPd0F3a3BManZEQldtZ0hQZW4tWC1kdDVoQ2tKMjM4ai1OMmEzT1ZLNzJIajNJaWd6U2FGMjByc1RZQWNCMTJ6NF9WLWFSTXh0NWpxVGI4dnlnSm1NUFVvZkszdUduLXFJVTJfZmhNR251dVk4RWE0ZWpwd1Bub1FPTWtSb05GdFNvSVE3elhHbTFFV3dnQ3FRQmhJcnF6a2Y2cllRZ0ZieHEzZHVBaTJZTmxKSFVicE45eE04?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-17T06:33:10+00:00", "published_display": "17 Jul 2026 06:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon accelerates trial timelines as enrolment completes", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOdXNyTUVNblFpbDFPZndkQ1hva29Kc3J1M0h3NlhBYlRvUDNVaWsyZzNROXJTczNndVZjZU5HbGlBcEhORktEYkdCQlpHWUZKWVNNZEdZZ19HdzJLRFhxYUQzTmUzdFRBb1NmVU1nUzR2VFowOUNNZk00NmE5OEd1RE1mVm9Md0JMRW9od2p1LW5feTFVdFZ3Q19lOA?oc=5", "source_name": "grafa.com", "published_at": "2026-07-17T03:00:35+00:00", "published_display": "17 Jul 2026 03:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Neurizon Therapeutics (ASX:NUZ) Leading the Next Wave of ASX Biotech Small Caps?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxON253NC1NZmJHY1dFRGhNdmJVamVEcmJwaGpuT0pnbTI2TWdBVm5NQUJKX1JzQ3Rja2xPZFhKcjNiQnVoOUFBVTBDLUtWdVA3ODBZN1FUVURsbk4tenhHZHQzdzViUGEwX2N1QmVIcnVVZ0h4Q0lra05xQXBnaDh0d3cxcFVnUVNCcVFVdmRHczZPdDh6QVJFZnloazB3X3dEaTVHWGxaZ1NaZnBPaEVpVDFxaHlZQ0NNYjJ0Y2FpamlKQnBUTUE?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-15T04:30:00+00:00", "published_display": "15 Jul 2026 04:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon Therapeutics (ASX:NUZ) Reaches Key ALS Trial Milestone", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQTUh5S2RGZjFFbkVRanljY2poYnVSVjRDOS1NbHFMWjg3Z3dQcm1DQm41eDMtbEFxMzY5OWl2UTNBZkVieTJOV3ZrZGIyZ3psbkR3MjFUbk1qMVhfWV81LUNUalNQcEtBX1BISU9pWFVtb08zVE5kLWFyOVNCcWRfTVUxRXMwUGxTQVA1YkxUb20yU3dTaEhTQlppaVFOQ3NNcUNKeDVpMA?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon director Marcus Hughes lifts stake with June share purchases", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQTTY0SmNDeTZEUmhhMkVhdGJQa3JQNnVXNUZDa3E5ZWVhaWhrMkhaM1dwcWN4RnNydGxaYmZYdXBkOFNvTnJ1SkdONmpFbWNBS2dUWDVfUmFLUDk5M25YTUF2X1BrWVZ1NDQ1dC1QOXdBMUcxWllwUFR2RVpvTzh4eEhPUlpjSVN4WFNQNFdjd3cyRUFPSHEyQlYzRjBNQXNGczkxMTd2Vk5nOTlWX1BXMEVMZTZ4bmU3ZDNYOGF2WW9LTmEzWTEzUEVpUUhNd1A2SFNWNTkxdU9wWEd2N09vN080NG8?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon (ASX: NUZ) Unveils New NUZ-001 ALS Mechanism Data at BIO International Convention 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPOHR3VXAyMG54anhDWXBBVEVlRC1vZWl0bkhOMEJ2bVpEUFhYQVhqWEhqcjB2cURpc1VuaW1BSlRtR09BRWdIZ2c2ck1ScDBxZTBzV2lWOXpmclVmYVZLNDU3a2lyRFBka1RGMHlNLU9hNlM5UUp6UHZ2TzR1ZndhRHlPSkxiWUZzVVVtYmNBZVJDZGdvRk10bXVNamx5U2NOQmhUa2ZPZG1lSzVXLWxLRDhZbVlGRmdaWG5aQVhJc1V2cVVael8yYWJpdw?oc=5", "source_name": "Kalkine", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX: NUZ \u2014 Neurizon Therapeutics Locks In Drug Supply as MND Program Momentum Builds", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQX2hQZHVOVExDNnlHNnYxS3c5SDNIVGZoZnFmNE51WnROTUlBSEJrUkNnMnJQU0VOdHlybzlBY1hrWU1FckFHVFRLOFlkbFU5VkpBOTVKX25wbGNKUU1mYmNhdDJuMFA1S2Z2Vl8yN3BNQmVQZ1BTSEk3VG0yRXczSnY3ZnVQT1VXenJtZ255U2Z5X1pGVUZFSzc5OWJKRzlOMTZLUnZONEU2cGt3NDNFekd2ZWhnRGxGNmdYSw?oc=5", "source_name": "Kalkine", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon Therapeutics (ASX NUZ) Shares Jump After Elanco Supply Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQMU12UlRtanA2TGNjcF91MkMzWmprOGlYbGJsal9IMGhvWUlNVWlsVWVDRHhuVzJqNXltcUthS3NBVjdIU1gzaVRseW1RLVN3MVdVYjZTVEVuLXo5SE14XzZ5ZlZ1RThyVEhiN0s3V0J2bVZSNkgxTXEyc19ZT0tCczk5eThJWXN0T3h6R1NYRnFZbVJLWTVycjdtTk1TRTcxWFo1Z3hGTUk?oc=5", "source_name": "Kalkine", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon Therapeutics (ASX:NUZ) Is in Focus Following HEALEY ALS Trial Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPTTEzOWZIVWVFMkptRnNxZ1FnREl5TkREaUwtNGNPaTdTUU9iWVFmZFBDUVotdGNReFFzRkFwQWhkT0pGSWpIOXR6c0JETUxBRmxZZXZXT2JrbWtDd3hJNXRTRERDTWI3Z3JTLVY1UTh6dFMtNU84VFFCZV9XTXMzNGhLT0xuVnE1eUdtRGRjQngzaHJldFVHa3N5OWNLcWtxSDFad0ZlN1ByUS1rTDg2Uk5Vbw?oc=5", "source_name": "Kalkine", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Neurizon launches $11.3m shortfall auction after rights issue", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQNGJoRTRHOTJoRzBMTjZEUEVxOUVzei1HLUdNWEdmYlNVLWRLVFRYUXRCRG1nMzRZV3VLX2RoMm9iYy14SFFlYm5fNV9jZVFTVHJhcG03SHFYb0RMTWdIWUpYeHJEOGhsWERuWWp1SThBTEtkLTBIdk9TdnVZTmxLNnNLRHRHcFZjckZiazZ6clFIc0VORGdjZDlITmgxRUQyY0QtZlIyTTJ5bkZSRzUxX2JwajNEME0?oc=5", "source_name": "AFR", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon Therapeutics (ASX:NUZ) Rises as New Data Strengthens Case for ALS Drug Candidate", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNb0V0VTlscy10ZDZmX1g0eXRFclFzM0U5MUVKa1VGVU5KaGVrMENkaERSR2NGb3Badk9Xa3M0Q3dnQThYUGduVDR1cWtERGc1WVFiaDV0R0N3aEJTaXZIbVN4QlN3dVg0aFFrZmNBS3RWR2lYNDdtaTBPNlJNUmFtSWplcTVXLV91THAzSTUzeUlEdFFzOVliTERiTERESGFYSEtWU091RkY1NUNtUm9za3dkcm53LXYxdjNLaDBQaER4aVk?oc=5", "source_name": "Kalkine", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon Therapeutics Chief Executive Officer Resigns, Shares Down 13%", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOcWpndllPSTV4WTFuYzVMN1ltcWQxSWNWYVNma2xTd284VW9zY0xyR3RpWkhNTXJaaEFzd1llbFdHbmNfS21lNVYxMGFodFBRV1VQOHlnRGtubE4yS3NQM29vLW1mRVBBVWJiOUhGckJHTXIzY3BZZThKQUZIOGtnTUEwNk1iRF9IRG5LRGhxbG41NjJ4cEc0bUxqd3U3S0VtZkViMHJEdGxHazRVTHNZ?oc=5", "source_name": "Moomoo", "published_at": "2026-03-15T07:00:00+00:00", "published_display": "15 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNYmt3SXFUcVdrVFR5elV5NVFMTUg1OUstdDZvWHhrbEtXaXpZVVRtQ0k3YWVTbVZzYTNuUF9qb2hfc1NNNFFkVF9tanBfSDZmRWtnV2tEWEpJT2xyN1VLaDRUX2pwTnBqVVlrdmNVUTdaZm1XSTM0d2Z5WlM2UjB6YklyTlRTZ0M5VGlid1d4b3NsUVJDN1hfR3dlMlItam03V2s5M09aaTFZaFdtWGR5a3p0RERyaGFfbzFBc2V3?oc=5", "source_name": "PR Newswire", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon locks in global trademark protection", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Australian", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon Therapeutics Secures Over $44M in Funding to Advance HEALEY ALS Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQSWtOcWUtMXlWOEtRQnoxUmpYSjhlWVc1UTZiclZ6WVZ5LU5mUm15UUtYTnlrc3NUbWlzVGdrUnN3WDVpR2JpTzRjY2JoNnJMc1BSUjMweE1NTmhJVWFxRHdKclNvakgzQVZkYlZEUTZsbUM1WTZ6TmNjRkF2ejRXSExkd2UteEc3bjlJMDRxbC1FTURHMTFIM2o3TW44Z0ljSDdwZFZMUUVacDZDMEtF?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-12-22T08:00:00+00:00", "published_display": "22 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insights: Neurizon Therapeutics Ltd (ASX:NUZ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFB6TkZXNVo4c09WSXdwYnJtTjNOVW5SOHRsOXhzUXlOTzNDUWstVU5MT3prNjlJRGZBV25xSzBWLWEzVGUzeDQ4ajNBem1lQ3pS?oc=5", "source_name": "smallcaps.com.au", "published_at": "2025-10-30T16:22:03+00:00", "published_display": "30 Oct 2025 16:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Break it Down: Neurizon secures Australian patent for its lead ALS drug candidate", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOT2lKal9McEhWeHJiT3c0WHRvT1k0Qk9KblZabmhiVV84ZlZHMkd0UXRWYjdJeVYwRmdNcm5GSmZNRGtCbGlFS211Z3pMVHZUaDNIZUZaSDZXRTdMWkJiNUtCbTljYWF2ZEdRc3d4dFM0TVZzYThncUlnMlViNGRfMDViaWpsQ29CUDRsOWYxUFljZ3VkVVFlRFlQeE5ncUhFUE5DeC1QeGlVaDk1bDZsY2lCOHdHU1BfWlVTLUVDMFk5em00c0RTMEZDZ0NKUQ?oc=5", "source_name": "Stockhead", "published_at": "2025-10-21T07:00:00+00:00", "published_display": "21 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "On track: Analysts hail FDA lift as turning point for Neurizon\u2019s ALS therapy ambitions", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOcjYyUEZBM3V0dEtXR1AxbHVVY1puVmhBaS1tSUNhVVpzMWdfNkRpSXJLTVhXNGxiOTlzU09aaF9DaUtxZ1JDTXo3Tjh4Yk1UVEpIZ25vY0ZiYzBIbTVMNUVhOUlxWVF2WjBROFhTUG5RZ0lEeFYxc0dQTXRwTFB6SWdxQU92dGdLb0hwNGRGTXNwNFR6RG45S3lvdzY1NjJvRzl3?oc=5", "source_name": "Stockhead", "published_at": "2025-10-09T07:00:00+00:00", "published_display": "09 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Lifts Clinical Hold on Neurizon Therapeutics Lead Investigational Drug NUZ-001", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQaDBOSFlpOG02M192TDQ4cVRWbG9SRVVGLVJZejRyYTVMMzc0cVFDUmhWcUNaNVRvXzRmcmJNalRGMzBZLUZwNlZGZXVnZ2ZtNVdlWF9ZeUJQTHBXV2pnczRpOEVnbnF6R1VDc0tnSko5cVlGaVl0VGZHZ3JEU3VGNmJYLXp4V3doWVlpckhLWE41a1k4cWhDa0xsMkhZeGY0NmJYQ1lESTc?oc=5", "source_name": "Pharmaceutical Executive", "published_at": "2025-10-06T07:00:00+00:00", "published_display": "06 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neurizon Therapeutics Limited (ASX: NUZ) - Announcements", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNTHNOLU1nQmdFei1NUC1EVHdmLVZnckYyR19QZjU5N0xlTVpHQ3poQ3BzQnRPZVVKbldBOEptaXpCbjFNRjAzN2N4S2RTaF92aU9hNWg2S2tIZU0tWm5JVjZfTUJiRV9JdVRmM215bXBydTdkMHNoa3VrVGhUdzFPeTBkN0VyR1J6LWNtZHNiQ1FFeW5FTGxVX04yOHFydw?oc=5", "source_name": "intelligentinvestor.com.au", "published_at": "2024-10-15T07:18:47+00:00", "published_display": "15 Oct 2024 07:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmAust affirms corporate strategy with name change to Neurizon Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNZkFfRzJNRjRfbmotaXF2dFhrQkFmNWpYWlJTbDJOcFR1Nk90Z0R3OXUzQWVTa00zZzlZa01DcXplUUxqN3RqNWwyWE1KaDNxTmFQVXpuNnhzZDd2YkZOMTIteURPWFYtMGE0aWRkWHNCTXZ6bUc2X1NBcDEzeEVzaTM1RHlEWmU1QW1qS1I4cEw0Q05SUkhjYUl0X0lnSzl6alFES3hBVHVUaHgyeG1yQUFuTmx0eWtWQ2E3WHVqbWRyLXpndmRyRlVGcFJwZEk?oc=5", "source_name": "PR Newswire", "published_at": "2024-10-15T07:00:00+00:00", "published_display": "15 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PharmAust rebrands as Neurizon Therapeutics", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Australian", "published_at": "2024-10-15T07:00:00+00:00", "published_display": "15 Oct 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NUZ Stock Price and Chart \u2014 ASX:NUZ", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE9NdmdHSEFWWjQ0bDVxRC1mbjl6SkdEbUU5UzhabE5ESVc2U0JqQWpia0VnU2YzNDUydjU2Y2ROMThsQ0lSZHhXMS1tTUswUWVpTUZfLWJDUQ?oc=5", "source_name": "TradingView", "published_at": "2024-10-15T01:37:38+00:00", "published_display": "15 Oct 2024 01:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 81, "total_relevant": 24, "sentiment_summary": {"positive": 0, "negative": 0, "neutral": 24, "score": 50, "total": 24, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 88, "events": [{"event": "general", "label": "Market update", "weight": 10.45, "count": 19}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 0, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 0.07, "latest_week": "2026-07-10", "one_week_move": -4.3, "four_week_move": 3.1, "twelve_week_move": -21.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.284521, "market_dynamics_buy_signal": false, "relative_strength": -35.754169, "fair_value_gap": -53.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 35.5629, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.3% over one week, +3.1% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Kalkine", "count": 6}, {"label": "Kalkine Media", "count": 2}, {"label": "PR Newswire", "count": 2}, {"label": "The Australian", "count": 2}, {"label": "smallcaps.com.au", "count": 2}, {"label": "Stockhead", "count": 2}, {"label": "Stock Titan", "count": 1}, {"label": "grafa.com", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 24}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 19}, {"label": "Deals and strategy", "count": 2}, {"label": "Earnings", "count": 1}, {"label": "Macro sensitivity", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "88/100 classification confidence."}, {"label": "Company focus", "value": "24", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.3% over one week, +3.1% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "What Does Faster Trial Enrolment Mean for Neurizon Therapeutics (ASX:NUZ)?"}], "updated_at": "2026-07-17T18:47:31.750990+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}